- Home
- CTO vs EYPT Comparison
CTO vs EYPT Comparison
Compare CTO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | EYPT |
|---|---|---|
| Founded | 1902 | 1987 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 1.3B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTO | EYPT |
|---|---|---|
| Price | $20.17 | $13.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $22.50 | ★ $31.80 |
| AVG Volume (30 Days) | 234.1K | ★ 792.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | $3,115.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $5.46 |
| 52 Week High | $20.67 | $19.11 |
Technical Indicators
Market Signals| Indicator | CTO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 46.75 |
| Support Level | $19.22 | $12.66 |
| Resistance Level | $20.67 | $14.54 |
| Average True Range (ATR) | 0.38 | 0.76 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 63.85 | 45.35 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.